Christopher Chien, MD
Advanced Heart Failure and Transplant Cardiology · Portland, ORNPI 1477732535
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,066 of the $57,328 with a category attached, or 64.7%. 14 manufacturers reported payments, led by Abbott at 54.4% of the total. Reporting peaked in 2022 at $14,338 and has fallen 61.7% since, to $5,490 in 2025.
Across 186 payments — averaging $308.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$31K
- Boston Scientific$13K
- Biotronik Inc.$8K
- Cvrx, Inc.$2K
- AstraZeneca$2K
- Abiomed$762
- plus $276 from 8 others
Across 90 payments — averaging $15,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$916K
- Abbott$299K
- Boehringer Ingelheim$85K
- AstraZeneca$68K
- Boehringer Ingelheim Pharma GmbH & Co.kg$12K
- Boehringer Ingelheim Canada Ltd.ltee$281
- plus $246 from 1 others
What the payments were for
- Consulting fees$37,06665%
- Travel & lodging$14,00424%
- Food & beverage$6,24511%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 118 | $31,190 |
| Boston Scientific | 12 | $13,121 |
| Biotronik Inc. | 15 | $7,908 |
| Cvrx, Inc. | 12 | $2,355 |
| AstraZeneca | 6 | $1,716 |
| Abiomed | 10 | $762 |
| Novo Nordisk | 3 | $83 |
| Novartis | 2 | $52 |
| Pfizer | 2 | $37 |
| Endotronix, Inc. | 1 | $27 |
| Bayer | 1 | $26 |
| Amgen | 2 | $25 |
| Sensible Medical Innovations Inc | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$11,000
- CARDIOMEMS$8,056
- CardioMEMS HF System$6,366
- MitraClip$5,808
- HeartMate 3 Left Ventricular Dev$3,688
- BioMonitor$2,625
- HeartMate 3 Left Ventricular Assist Device$2,600
- Barostim Neo System$2,142
- GENERAL - THERAPIES$1,818
- FARXIGA$1,628
- Cardiovascular- Research only$1,456
- AMVIA EDGE$579
- Edora 8 DR-T$579
- Sentus$579
- Rivacor 7 DR-T$579
- Acticor 7 VR-T DX$579
- HeartMate II LVAS$484
- HeartMate Touch$470
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$463
- RESONATE$283
How this compares
Too few advanced heart failure and transplant cardiology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 147 | $181,558 |
| FarxigaDapagliflozin Propanediol | 51 | $50,165 |
| EliquisApixaban | 41 | $47,466 |
| JardianceEmpagliflozin | 23 | $32,011 |
| Metoprolol Succinate | 143 | $2,725 |
| Torsemide | 103 | $2,341 |
| Spironolactone | 154 | $1,335 |
| Potassium Chloride | 31 | $988 |
| Amiodarone Hcl | 19 | $936 |
| Atorvastatin Calcium | 48 | $643 |
| Carvedilol | 59 | $481 |
| Losartan Potassium | 64 | $401 |
| Pravastatin Sodium | 17 | $368 |
| Digoxin | 11 | $331 |
| Rosuvastatin Calcium | 23 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $52 | $181,558147 claims |
| AstraZenecaFarxiga | $1,716 | $50,16551 claims |
| PfizerEliquis | $37 | $47,46641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Portland
- Jacob AbrahamPortland$331K
- Joshua RemickPortland$143K
- Jenna KayPortland$37K
- Vidang NguyenPortland$27K
- Conrad MaconPortland$13K
- Johannes SteinerPortland$9K
- Luke MashaPortland$3K
- Nalini ColacoPortland$2K
- Deborah MeyersPortland$2K
- Divya SomanPortland$946
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.